Early Stage Partners is a private equity firm based in Cleveland, Ohio, founded in 2001. The firm specializes in investing in early-stage technology companies across various sectors, including information technology, healthcare, manufacturing, and industrial technology. With a focus on the Midwest, Early Stage Partners aims to support and nurture innovative companies that have the potential for significant growth and impact in their respective industries.
1801 East Ninth Street, Suite 1700 Cleveland, OH 44114
Mike Bunker
Managing Director
Charlie MacMillan
CFO
38 past transactions
HistoSonics
Series B in 2017
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.
OnShift
Series D in 2016
OnShift is a provider of cloud-based human capital management software specifically designed to address workforce challenges in post-acute and long-term care facilities. The company's platform includes a comprehensive suite of tools for hiring, scheduling, employee engagement, and talent acquisition, aimed at enhancing productivity and profitability for healthcare organizations. With features such as predictive analytics and intuitive design, OnShift empowers clients to maintain a consistent and engaged workforce, ultimately driving quality care and reducing operational costs. Thousands of senior living and post-acute care organizations rely on OnShift's solutions to effectively manage their staffing needs and improve overall performance.
Amplifinity
Series B in 2014
Amplifinity, LLC, founded in 2007 and based in Ann Arbor, Michigan, specializes in developing and delivering referral programs for Fortune 500 companies. The company offers the Advocate Management Platform (AMP), which provides tools for launching and managing word-of-mouth marketing campaigns. Key features of AMP include the Program Builder, which allows users to design and analyze multiple advocacy campaigns, and the Advocate Database, which maintains individual profiles for advocates. Amplifinity's software automates the tracking and management of B2B customer and partner referrals, ensuring smooth reward fulfillment and incentive structures. The platform is integrated with Salesforce to enhance referral productivity. Companies across various sectors, including travel, financial services, and home goods, utilize Amplifinity’s services to streamline their referral programs and improve customer acquisition. Amplifinity operates as a subsidiary of Impartner Software, Inc.
OnShift
Series C in 2014
OnShift is a provider of cloud-based human capital management software specifically designed to address workforce challenges in post-acute and long-term care facilities. The company's platform includes a comprehensive suite of tools for hiring, scheduling, employee engagement, and talent acquisition, aimed at enhancing productivity and profitability for healthcare organizations. With features such as predictive analytics and intuitive design, OnShift empowers clients to maintain a consistent and engaged workforce, ultimately driving quality care and reducing operational costs. Thousands of senior living and post-acute care organizations rely on OnShift's solutions to effectively manage their staffing needs and improve overall performance.
Juventas Therapeutics
Series B in 2012
Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.
OnShift
Series B in 2012
OnShift is a provider of cloud-based human capital management software specifically designed to address workforce challenges in post-acute and long-term care facilities. The company's platform includes a comprehensive suite of tools for hiring, scheduling, employee engagement, and talent acquisition, aimed at enhancing productivity and profitability for healthcare organizations. With features such as predictive analytics and intuitive design, OnShift empowers clients to maintain a consistent and engaged workforce, ultimately driving quality care and reducing operational costs. Thousands of senior living and post-acute care organizations rely on OnShift's solutions to effectively manage their staffing needs and improve overall performance.
LineStream Technologies
Series B in 2012
LineStream Technologies, Inc. specializes in developing control technology and software solutions aimed at enhancing the performance of automated products and processes. Founded in 2006 and based in Cleveland, Ohio, the company provides embedded software that integrates into a variety of applications, from household appliances like washing machines to advanced manufacturing equipment. LineStream's software is designed to actively reject process disturbances, thereby mitigating potential degradation of system performance. This capability allows businesses to achieve improved efficiency while simplifying control and tuning processes. Formerly known as ADRC Technologies, Inc., the company rebranded in March 2010 to better reflect its focus on innovative control technologies.
CytoPherx
Series C in 2012
CytoPherx (formerly Nephrion) clinical stage medical device company addressing inflammation-based diseases and conditions. The company’s products are custom configurations of a proprietary selective cytopheresis-based inflammation modulating system.
Amplifinity
Series A in 2011
Amplifinity, LLC, founded in 2007 and based in Ann Arbor, Michigan, specializes in developing and delivering referral programs for Fortune 500 companies. The company offers the Advocate Management Platform (AMP), which provides tools for launching and managing word-of-mouth marketing campaigns. Key features of AMP include the Program Builder, which allows users to design and analyze multiple advocacy campaigns, and the Advocate Database, which maintains individual profiles for advocates. Amplifinity's software automates the tracking and management of B2B customer and partner referrals, ensuring smooth reward fulfillment and incentive structures. The platform is integrated with Salesforce to enhance referral productivity. Companies across various sectors, including travel, financial services, and home goods, utilize Amplifinity’s services to streamline their referral programs and improve customer acquisition. Amplifinity operates as a subsidiary of Impartner Software, Inc.
SironRX Therapeutics
Series A in 2011
SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.
TOA Technologies
Series D in 2011
TOA Technologies offers cloud-based field service management software designed for businesses operating in various sectors, including telecommunications, utilities, healthcare, and retail. Their primary product, ETAdirect, utilizes a patented time-based predictive analytics platform to optimize mobile field service operations. This software learns from individual employee performance to identify patterns and predict the most efficient routes based on real-time data. By effectively communicating updates to consumers throughout the service process, ETAdirect enhances operational efficiency, reduces customer wait times, and increases overall productivity for field service teams.
OnShift
Series A in 2010
OnShift is a provider of cloud-based human capital management software specifically designed to address workforce challenges in post-acute and long-term care facilities. The company's platform includes a comprehensive suite of tools for hiring, scheduling, employee engagement, and talent acquisition, aimed at enhancing productivity and profitability for healthcare organizations. With features such as predictive analytics and intuitive design, OnShift empowers clients to maintain a consistent and engaged workforce, ultimately driving quality care and reducing operational costs. Thousands of senior living and post-acute care organizations rely on OnShift's solutions to effectively manage their staffing needs and improve overall performance.
AxioMed
Series D in 2010
AxioMed LLC specializes in designing and developing disc replacement devices aimed at alleviating neck pain and restoring normal spinal functions for patients suffering from degenerative disc disease. Founded in 2001 and based in Malden, Massachusetts, the company was previously known as AxioMed Spine Corporation until its name change in 2014. AxioMed has developed the Freedom® Lumbar Disc and initiated clinical trials for its products, which are intended to improve the standard of care beyond traditional fusion and first-generation artificial discs. The company is led by CEO Patrick McBrayer and COO James Kuras, who oversee a team with extensive experience in spinal implants and engineering. They are supported by a Medical Advisory Panel of surgeons from prominent spine centers and universities. AxioMed's operations encompass product development, testing, clinical and regulatory affairs, and manufacturing, with ongoing projects focusing on cervical spine solutions.
Prevacept Infection Control
Series B in 2010
Prevacept Infection Control is a clinical-stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters.
Intelligent Clearing Network
Venture Round in 2010
Intelligent Clearing Network, Inc. is a software-as-a-service company that specializes in the electronic validation and clearing of paper and digital coupons, as well as other incentives, for grocery, drug, and mass merchant retailers. Founded in 2008 and based in Connecticut, the company provides a fully automated promotion management system that allows retailers to maintain control over their promotions while significantly reducing the risk of fraud. Its services include promotion management, coupon validation, fraud protection, and direct-to-card offers. By facilitating real-time validation at the point-of-sale, Intelligent Clearing Network addresses issues related to misredemption and fraudulent coupon use, delivering real-time redemption information to manufacturers, media companies, and retailers when incentives are processed.
Reverse Medical
Series B in 2010
Reverse Medical is a commercial-stage medical device company dedicated to developing innovative solutions for revascularizing patients suffering from acute ischemic strokes. The company specializes in creating embolic protection systems aimed at treating neurovascular disorders, with a strong emphasis on endovascular management of acute stroke conditions. Through its advanced medical technologies, Reverse Medical seeks to improve patient outcomes and enhance the overall standard of care in the treatment of stroke.
HistoSonics
Series A in 2010
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.
Juventas Therapeutics
Series A in 2008
Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.
EcoSMART Technologies
Venture Round in 2008
EcoSMART Technologies, Inc. specializes in the manufacture of pesticide solutions and pet care products derived from natural ingredients. Founded in 1992 and headquartered in Atlanta, Georgia, the company offers a comprehensive range of pest control items, including insecticides for ants, roaches, bed bugs, fleas, ticks, and garden pests, as well as weed and grass killers. Its formulations utilize essential plant oils, which have been shown through scientific research to effectively disrupt insect neuro-receptors, providing a non-toxic alternative to traditional synthetic chemicals. EcoSMART's products are designed to be safe for both residential and commercial use, and they are available through online platforms and retail stores. As a subsidiary of Kittrich Corporation, EcoSMART is committed to producing effective and environmentally friendly solutions in the pest control industry.
LineStream Technologies
Series A in 2008
LineStream Technologies, Inc. specializes in developing control technology and software solutions aimed at enhancing the performance of automated products and processes. Founded in 2006 and based in Cleveland, Ohio, the company provides embedded software that integrates into a variety of applications, from household appliances like washing machines to advanced manufacturing equipment. LineStream's software is designed to actively reject process disturbances, thereby mitigating potential degradation of system performance. This capability allows businesses to achieve improved efficiency while simplifying control and tuning processes. Formerly known as ADRC Technologies, Inc., the company rebranded in March 2010 to better reflect its focus on innovative control technologies.
Imalux Corporation
Series C in 2007
Imalux Corporation, an Ohio medical device company, is positioned to become the worldwide leader in the commercializationPhoto of medical imaging equipment and devices based on its proprietary Optical Coherence Tomography (OCT) technology. The Company’s products provide real-time, high spatial resolution imaging at the point-of-care in a variety of medical applications. OCT is a new imaging modality for visualization of tissue microstructure, especially in anatomical areas with stratified tissue. It has the ability to detect near-surface tissue abnormalities indicative of disease, which established imaging modalities might not detect. Many diseases, including cancer, are associated with superficial tissue structure disruption. Today, there is no commercialized in vivo method to visualize this tissue structure alteration; clinicians must do a biopsy and an ex vivo histopathological review using a conventional microscope. Imalux OCT products can be used to visualize structural disruptions in vivo at the point of care.
Blue Spark Technologies
Series A in 2007
Blue Spark Technologies, Inc. specializes in producing thin and flexible battery solutions for wearable and printed electronics. The company offers carbon-zinc batteries tailored for original equipment manufacturers, product design engineers, and system integrators across various industries, including healthcare, pharmaceuticals, and consumer products. Notably, Blue Spark develops TempTraq, a wearable thermometer that tracks and transmits a child's temperature to mobile devices, enhancing health monitoring for caregivers. Established in 2002 and headquartered in Westlake, Ohio, the company was initially known as Thin Battery Technologies and rebranded in 2008. With a focus on innovative power source solutions, Blue Spark Technologies leverages patented technology to meet the evolving needs of battery-powered electronic systems.
Five Star Technologies
Venture Round in 2006
Five Star Technologies is a supplier of high-performance dispersions, inks and pastes used in displays, photovoltaics, and microelectronic packaging. Combining its patented hydrodynamic cavitation process with innovative chemistry, Five Star produces the ElectroSperseâ„¢ series of inks and pastes as well as a wide range of precision dispersions. The ElectroSperse line features a range of conductive pastes with exceptional printability, low firing temperatures, high levels of conductivity, strong adhesion to a variety of substrates, and RoHS compliance. ElectroSperse grades can be tailored for a range of processing techniques, including screen, gravure, extrusion and ink jet printing. Targeted applications include electrodes, interconnects, and linearization patterns for displays, photovoltaic front side contacts, and hybrid microcircuits.
EcoSMART Technologies
Series C in 2006
EcoSMART Technologies, Inc. specializes in the manufacture of pesticide solutions and pet care products derived from natural ingredients. Founded in 1992 and headquartered in Atlanta, Georgia, the company offers a comprehensive range of pest control items, including insecticides for ants, roaches, bed bugs, fleas, ticks, and garden pests, as well as weed and grass killers. Its formulations utilize essential plant oils, which have been shown through scientific research to effectively disrupt insect neuro-receptors, providing a non-toxic alternative to traditional synthetic chemicals. EcoSMART's products are designed to be safe for both residential and commercial use, and they are available through online platforms and retail stores. As a subsidiary of Kittrich Corporation, EcoSMART is committed to producing effective and environmentally friendly solutions in the pest control industry.
TetraLogic Pharmaceuticals
Series B in 2006
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.
GoTo
Series B in 2005
GoTo, formerly known as LogMeIn, is a provider of cloud communications and IT solutions, focusing on flexible work software. Its product suite includes GoTo Connect, GoTo Resolve, Rescue, and Central, catering primarily to small and midsize business IT departments while also being suitable for enterprise applications. GoTo's platform facilitates unified communications and collaboration as well as IT management and support, boasting nearly 800,000 customers and enabling over 1 billion participants in various online interactions. The company emphasizes secure, reliable, and AI-enabled solutions that are easy to implement and scale. Headquartered in Boston, Massachusetts, GoTo generates approximately $1 billion in annual revenue and employs around 2,800 individuals across multiple continents.
Unitask
Series A in 2005
Unitask, Inc. develops and sells software solutions designed to automate tasks related to the management and operation of Oracle E-Business Suite (EBS). Founded in 1994 and headquartered in Bloomfield Hills, Michigan, with additional operations in Israel, the company offers products such as Unitask Output Director, which streamlines output management by automating printer configurations and enabling users to print, fax, email, and store Oracle EBS reports. Another key product, Unitask Migration Director, facilitates the automation of code migrations within Oracle EBS instances. Additionally, the Unitask Command Center provides a web-based interface for managing these automation solutions. Unitask's software is utilized across a variety of industries, including oil and gas, manufacturing, healthcare, and government, serving customers globally in regions such as North America, South America, Europe, Asia, and Africa.
TOA Technologies
Series B in 2005
TOA Technologies offers cloud-based field service management software designed for businesses operating in various sectors, including telecommunications, utilities, healthcare, and retail. Their primary product, ETAdirect, utilizes a patented time-based predictive analytics platform to optimize mobile field service operations. This software learns from individual employee performance to identify patterns and predict the most efficient routes based on real-time data. By effectively communicating updates to consumers throughout the service process, ETAdirect enhances operational efficiency, reduces customer wait times, and increases overall productivity for field service teams.
AxioMed
Series B in 2005
AxioMed LLC specializes in designing and developing disc replacement devices aimed at alleviating neck pain and restoring normal spinal functions for patients suffering from degenerative disc disease. Founded in 2001 and based in Malden, Massachusetts, the company was previously known as AxioMed Spine Corporation until its name change in 2014. AxioMed has developed the Freedom® Lumbar Disc and initiated clinical trials for its products, which are intended to improve the standard of care beyond traditional fusion and first-generation artificial discs. The company is led by CEO Patrick McBrayer and COO James Kuras, who oversee a team with extensive experience in spinal implants and engineering. They are supported by a Medical Advisory Panel of surgeons from prominent spine centers and universities. AxioMed's operations encompass product development, testing, clinical and regulatory affairs, and manufacturing, with ongoing projects focusing on cervical spine solutions.
Imalux Corporation
Series B in 2005
Imalux Corporation, an Ohio medical device company, is positioned to become the worldwide leader in the commercializationPhoto of medical imaging equipment and devices based on its proprietary Optical Coherence Tomography (OCT) technology. The Company’s products provide real-time, high spatial resolution imaging at the point-of-care in a variety of medical applications. OCT is a new imaging modality for visualization of tissue microstructure, especially in anatomical areas with stratified tissue. It has the ability to detect near-surface tissue abnormalities indicative of disease, which established imaging modalities might not detect. Many diseases, including cancer, are associated with superficial tissue structure disruption. Today, there is no commercialized in vivo method to visualize this tissue structure alteration; clinicians must do a biopsy and an ex vivo histopathological review using a conventional microscope. Imalux OCT products can be used to visualize structural disruptions in vivo at the point of care.
TetraLogic Pharmaceuticals
Series A in 2004
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.
Five Star Technologies
Series C in 2003
Five Star Technologies is a supplier of high-performance dispersions, inks and pastes used in displays, photovoltaics, and microelectronic packaging. Combining its patented hydrodynamic cavitation process with innovative chemistry, Five Star produces the ElectroSperseâ„¢ series of inks and pastes as well as a wide range of precision dispersions. The ElectroSperse line features a range of conductive pastes with exceptional printability, low firing temperatures, high levels of conductivity, strong adhesion to a variety of substrates, and RoHS compliance. ElectroSperse grades can be tailored for a range of processing techniques, including screen, gravure, extrusion and ink jet printing. Targeted applications include electrodes, interconnects, and linearization patterns for displays, photovoltaic front side contacts, and hybrid microcircuits.
Imalux Corporation
Series A in 2003
Imalux Corporation, an Ohio medical device company, is positioned to become the worldwide leader in the commercializationPhoto of medical imaging equipment and devices based on its proprietary Optical Coherence Tomography (OCT) technology. The Company’s products provide real-time, high spatial resolution imaging at the point-of-care in a variety of medical applications. OCT is a new imaging modality for visualization of tissue microstructure, especially in anatomical areas with stratified tissue. It has the ability to detect near-surface tissue abnormalities indicative of disease, which established imaging modalities might not detect. Many diseases, including cancer, are associated with superficial tissue structure disruption. Today, there is no commercialized in vivo method to visualize this tissue structure alteration; clinicians must do a biopsy and an ex vivo histopathological review using a conventional microscope. Imalux OCT products can be used to visualize structural disruptions in vivo at the point of care.
Netilla Networks
Series C in 2003
Netilla Networks specializes in providing secure remote access solutions for corporate networks through its Netilla Service Platform, which is recognized as a leading SSL VPN appliance. This platform allows organizations to offer secure access to any application, whether on Windows, UNIX/Linux, or mainframe systems, via standard web browsers. By integrating thin-client technology with SSL encryption, along with a robust authentication and policy framework, Netilla Networks enables rapid deployment and reduces network exposure. The system is designed to lower maintenance costs compared to traditional VPNs while ensuring a user-friendly experience.
AxioMed
Series A in 2003
AxioMed LLC specializes in designing and developing disc replacement devices aimed at alleviating neck pain and restoring normal spinal functions for patients suffering from degenerative disc disease. Founded in 2001 and based in Malden, Massachusetts, the company was previously known as AxioMed Spine Corporation until its name change in 2014. AxioMed has developed the Freedom® Lumbar Disc and initiated clinical trials for its products, which are intended to improve the standard of care beyond traditional fusion and first-generation artificial discs. The company is led by CEO Patrick McBrayer and COO James Kuras, who oversee a team with extensive experience in spinal implants and engineering. They are supported by a Medical Advisory Panel of surgeons from prominent spine centers and universities. AxioMed's operations encompass product development, testing, clinical and regulatory affairs, and manufacturing, with ongoing projects focusing on cervical spine solutions.
Netilla Networks
Series B in 2001
Netilla Networks specializes in providing secure remote access solutions for corporate networks through its Netilla Service Platform, which is recognized as a leading SSL VPN appliance. This platform allows organizations to offer secure access to any application, whether on Windows, UNIX/Linux, or mainframe systems, via standard web browsers. By integrating thin-client technology with SSL encryption, along with a robust authentication and policy framework, Netilla Networks enables rapid deployment and reduces network exposure. The system is designed to lower maintenance costs compared to traditional VPNs while ensuring a user-friendly experience.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.